{"nctId":"NCT04475432","briefTitle":"Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis","startDateStruct":{"date":"2020-09-09","type":"ACTUAL"},"conditions":["Blepharitis"],"count":421,"armGroups":[{"label":"Active","type":"EXPERIMENTAL","interventionNames":["Drug: TP-03, 0.25%"]},{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: TP-03 Vehicle"]}],"interventions":[{"name":"TP-03, 0.25%","otherNames":["Lotilaner ophthalmic solution, 0.25%"]},{"name":"TP-03 Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol\n* Meet all of the following criteria in at least one eye: Have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash\n\nExclusion Criteria:\n\n* Have used lid hygiene products within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study\n* Have worn contact lenses within 7 days of Screening or be unwilling to forego contact lens wear during the study\n* Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be unwilling to forego their use during the study\n* Pregnancy or lactation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants Cured Based on a Collarette Score at Day 43.","description":"The proportion of participants cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye.\n\nThe primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.439","spread":"0.034"},{"groupId":"OG001","value":"0.072","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Participants With Eradication of Demodex Mites in the Analysis Eye at Day 43","description":"The proportion of participants with Demodex mites eradicated at Day 43 where eradication is defined as a mite density of 0 mites/lash for the analysis eye. The mite density is obtained by epilating four of more lashes and dividing the number of mites observed under the microscope by the number of lashes.\n\nThe primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.677","spread":"0.032"},{"groupId":"OG001","value":"0.173","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Cured Based on a Composite Collarette and Erythema Score of 0 in the Analysis Eye at Day 43.","description":"The proportion of participants cured where cure is defined as a composite of the collarettes, 0-2 lashes with collarettes on the upper eyelid of the analysis eye, and normal lid margin erythema for the upper eyelid of the analysis eye at Day 43.\n\nThe primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.139","spread":"0.024"},{"groupId":"OG001","value":"0.01","spread":"0.007"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":212},"commonTop":["Instillation site pain","Visual acuity reduced","Instillation site pruritus","Eye pain","Eye discharge"]}}}